Developing a breathalyzer for disease – with a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by developing Breath Biopsy® for applications in early detection and precision medicine across a wide range of diseases. Breath Biopsy detects biomarkers on breath such as volatile organic compounds (VOCs) and respiratory droplets.

VOC biomarkers originate from within the body as a result of metabolic and disease processes as from external sources including diet, environmental exposures and the microbiome. They are carried in the blood and exchange into breath in the lungs. Respiratory droplets arise in the lungs and are a medium for respiratory disease transmission as well as a source of macromolecular and non-volatile biomarkers.

Owlstone Medical is establishing a new diagnostic modality in breath with distinct advantages over existing approaches. The company offers an end-to-end platform for sample collection and analysis to support clinicians, academics and pharmaceutical researchers. Their Breath Biopsy Collection station, including ReCIVA® Breath Sampler enables non-invasive sampling with background reduction and pre-concentration to maximize sensitivity. Owlstone Medical provides comprehensive sample analysis services through the Breath Biopsy OMNI Assay that delivers high quality biomarker discovery, identification and validation using Thermo Fisher™ GC-Orbitrap™ technologies. You can also target specific processes for precision analysis with EVOC® Probes; using administered exogenous VOCs to precisely assay metabolic pathways of interest.